Edition:
United States

ASKA Pharmaceutical Co Ltd (4514.T)

4514.T on Tokyo Stock Exchange

1,655JPY
30 Mar 2017
Change (% chg)

¥-45 (-2.65%)
Prev Close
¥1,700
Open
¥1,690
Day's High
¥1,698
Day's Low
¥1,654
Volume
66,600
Avg. Vol
111,756
52-wk High
¥2,231
52-wk Low
¥1,269

Latest Key Developments (Source: Significant Developments)

ASKA Pharmaceutical signs option agreement with Pieris Pharmaceuticals on anemia treatment drug PRS-080
Monday, 27 Feb 2017 09:03pm EST 

ASKA Pharmaceutical Co Ltd <4514.T> :Says the company enters into an exclusive option agreement with Pieris Pharmaceuticals on development and sale of anemia treatment drug PRS-080 in Japan, Korea and other Asian countries.  Full Article

Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical
Monday, 27 Feb 2017 07:30am EST 

Pieris Pharmaceuticals Inc : Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska Pharmaceutical . Pieris Pharmaceuticals Inc - co will receive an immediate option payment of $2.75 million usd from Aska . Pieris Pharmaceuticals Inc - a Phase 1 study conducted in healthy volunteers demonstrated that a single dose of PRS-080 was well tolerated . Pieris Pharmaceuticals Inc - Pieris may also receive double-digit royalties on net sales of PRS-080 up to mid- to high-teens . Pieris Pharmaceuticals Inc - PRS-060, anticipated to begin a first-in-human study around middle of 2017 . Pieris Pharmaceuticals Inc - PRS-343 scheduled to enter a first-in patient trial in first half of 2017 .Pieris Pharmaceuticals - should Aska exercise option, Pieris would be eligible for over $80 million usd in combined option exercise fee and milestones.  Full Article

ASKA Pharmaceutical forms business alliance with Nobelpharma
Wednesday, 30 Nov 2016 01:24am EST 

ASKA Pharmaceutical <4514.T> :Says it forms business alliance with Nobelpharma Co Ltd, regarding ethical pharmaceuticals of maternity and gynaecology field.  Full Article

ASKA Pharmaceutical amends consolidated full-year outlook for FY 2016
Monday, 25 Apr 2016 02:00am EDT 

ASKA Pharmaceutical Co Ltd:Says the company lowered the consolidated full-year outlook for revenue to 43,210 mln yen from 44,000 mln yen for FY ended March 2016.Sees an increased operating profit forecast to 1,160 mln yen from 800 mln yen.Sees an increased ordinary profit forecast to 1,520 mln yen from 1,000 mln yen.Sees an increased net profit forecast to 700 mln yen from 600 mln yen.Sees an increased earnings per share to 25.15 yen from 21.53 yen per share.Comments reduced costs is the main reason for the forecast.  Full Article

ASKA Pharmaceutical signs commercialization contract for treatment of hypertension with Takeda Pharmaceutical
Wednesday, 24 Feb 2016 01:00am EST 

ASKA Pharmaceutical Co Ltd:Says signed commercialization contract for a treatment of hypertension with Takeda Pharmaceutical on Feb. 24.Says ASKA Pharmaceutical obtain manufacturing and marketing approval for the treatment of hypertension from the Ministry of Health, Labour and Welfare in February.  Full Article

ASKA Pharmaceutical lowers consolidated full-year outlook for FY 2016
Wednesday, 4 Nov 2015 02:00am EST 

ASKA Pharmaceutical Co Ltd:Says the company lowered the consolidated full-year outlook for the FY ending March 2016.Revenue forecast decreased to 44,000 million yen from 47,000 million yen.Operating profit forecast decreased to 800 million yen from 2,000 million yen.Ordinary profit forecast decreased to 1,000 million yen from 2,200 million yen.Net profit forecast decreased to 600 million yen from 1,600 million yen.Earnings per share decreased to 21.53 yen from 57.44 yen.Comments that delay of new product and sales lower than expected are the main reasons for the forecast.  Full Article

More From Around the Web

BRIEF-ASKA Pharmaceutical signs option agreement with Pieris Pharmaceuticals on anemia treatment drug PRS-080

* Says the company enters into an exclusive option agreement with Pieris Pharmaceuticals on development and sale of anemia treatment drug PRS-080 in Japan, Korea and other Asian countries